Sumitomo Chemical's Record Year Is a Naphtha Trade With a Chemicals Company Attached
A JPY 270bn record profit guide leans on inventory marks and Petro Rabigh refining margins, while crop protection slips again and Singapore goes silent.
4005.T · Earnings Call · 2026-11-02
A record with a footnote
On the surface, this was Sumitomo Chemical's best first half in years: core operating income of JPY 144.5bn, up JPY 35.8bn, and net income attributable to owners of the parent of JPY 82.9bn, up JPY 43.2bn — the second-highest first-half on record. Management raised full-year core operating income guidance to JPY 270bn from JPY 250bn, a new record, lifted net income to JPY 90bn and added JPY 1 to the year-end dividend for JPY 17 annual.
Then the footnote. Of the three segments revised upward, the largest by far was Essential & Green Materials: JPY 20bn to JPY 75bn of full-year core operating income, a near-fourfold change in the group's long-standing problem child. That is not a demand story.
in the first half, inventory evaluation gains was posted, and about half we thought with the stabilization situation in the Middle East. Second half, we start with losses.
Roughly half the E&GM upgrade traces to inventory valuation gains created when naphtha spiked — the first half averaged JPY 107,500 per kiloliter against a full-year assumption of JPY 99,000 — and product prices rose with the Middle East situation. The other half is refining margin at Petro Rabigh. Both are mark-to-market and margin-cycle artifacts. Neither is a capacity addition, a share gain, or anything a shareholder can underwrite into 2028.
The half that didn't move
Agro & Life Solutions was left unchanged, which is itself the story. This is the segment that has been promised a recovery for the better part of a year. First-half core income of JPY 20.8bn, up JPY 9.6bn, came almost entirely from better methionine margins. Crop protection volumes did not cooperate.
“Overseas crop protection chemicals, demand recovery is delayed in Middle and South America. ... This year, Super El Niño is being mentioned. This impact seems to be seen somewhat in Brazil.” — Toshihiro Yamauchi, Managing Executive Officer · 2026-11-02
That is a new excuse vector. El Niño was the second-highest-momentum keyword in the whole market back in 20262, and it has now been promoted into Sumitomo's own crop protection products outside Japan narrative — alongside farmer credit stress in Latin America and a weak Indian monsoon. It is not a Sumitomo-only alibi: CWT, the water utility, cited a "super El Nino year" this quarter too. Weather is doing an unusual amount of work across chemical and utility calls right now. For Sumitomo specifically, the "recovery is coming" line has now slipped several quarters in a row.
Methionine is the other half. The market price distortions from a competitor's supply constraints are settling; management insists it will push raw material costs through to customers, but that is an aspiration, not a booked spread.
ICT is the one clean upgrade — with an unpriced lever
ICT & Mobility went from JPY 55bn to JPY 60bn. Semiconductor processing materials — resist and semiconductor chemicals — are the engine, helped by super engineering plastics riding Chinese stimulus in electronic components. Displays remain a drag, and the second half still carries normal seasonality.
The interesting moment came in Q&A. Asked whether Sumitomo would follow competitors in price revision, Yamauchi confirmed the direction but refused the arithmetic:
“in our case also, we are consulting with the customers and revise to an appropriate price level.” — Toshihiro Yamauchi, Managing Executive Officer · 2026-11-02
He would not size the increase, the spread, or the cost pass-through, citing labor and fixed costs alongside feedstock. For a franchise finally growing into AI-driven semiconductor demand, that spread is the number that matters for next year — and it is precisely the number management will not quantify.
What management stopped saying
The most telling item in this report is a keyword that is absent. Through 2024 and much of 2025, the Sumitomo story was structural reform and portfolio surgery: the Petro Rabigh stake reduction, the Sumitomo Pharma Asia divestiture, the Singapore optimization, the Keiyo Ethylene consolidation. Those concepts have fallen out of the narrative this quarter, replaced by Middle East margins and naphtha marks. That is a shift in what management believes is driving the equity — from self-help to commodity beta.
Which makes Singapore conspicuous. Asked directly whether something could surface there, Yamauchi declined:
“Apologies, I cannot speak about the content. I would like to refrain from commenting.” — Toshihiro Yamauchi, Managing Executive Officer · 2026-11-02
The force majeure at Singapore has still not been lifted, and operations remain near first-quarter levels. A year ago the tone was different — “So Singapore, for example, for PCS, we are studying the possibilities of optimization in TPC, MMA.” — Keigo Sasaki, Representative Director and Senior Managing Executive Officer · 2025-11-04 Silence after disclosure is itself information, and it deserves a discount in the quality of this beat.
Balance sheet, buffer, dividend
The D/E ratio improved sharply to 0.73x and the equity ratio to 32.1%, helped by Sumitomo Pharma's capital increase as much as by earnings. Interest-bearing debt fell JPY 64.1bn. That is genuine progress, and it sharpens the puzzle: leverage is improving through equity issuance and asset sales while earnings quality is increasingly reliant on market marks.
The second half is also salted in the familiar way. About JPY 10bn of unspecified risk sits in the Others line, and non-recurring items are expected to be back-half weighted, echoing last year's roughly JPY 55bn.
“For the other risk factors, money amount-wise, it is about JPY 10 billion that is incorporated.” — Toshihiro Yamauchi, Managing Executive Officer · 2026-11-02
Management was candid that this is a generic buffer rather than a specific item. The dividend dialogue has not changed shape either. Okazaki pressed on the JPY 24 per-share peak in February — “The annual dividend payout ratio is now about 40%. I think you mentioned 30% before.” — Shigeki Okazaki, Analyst · 2026-02-03 — and pressed again this quarter. Both answers amounted to: we would like to get there, but not yet.
The read
Notably, the market's own highest-momentum keywords this quarter are dominated by rate-cycle vocabulary — IRB model, Fed rate hike, core deposits. None of that touches Sumitomo's tape. This is a company-specific commodity and weather story, not a company riding a broad market wave — and the closest shared themes, Middle East Conflict and el niño, are inputs to the P&L rather than tailwinds behind the business.
The swing factor is whether record guidance of JPY 270bn is a floor or a cyclical peak. Two of the three upward revisions rest on feedstock timing and inventory marks that reverse if naphtha normalizes toward management's own JPY 99,000 assumption — the company itself models losses in the second half. The one clean upgrade, semiconductor materials, comes with a price lever management will not size. Until crop protection recovers and Singapore resolves, the record is a naphtha trade with a chemicals company attached.